TWO · 4127.TWO
Tien Liang BioTech Co., Ltd.
NT$34.85-NT$1.95 (-5.3%)
Tien Liang BioTech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.7% below the high.
Loading market information…
TWO · 4160.TWO · TWD
Stock price, dividends
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Genetics Generation Advancement Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Genetics Generation Advancement Corp.’s forward annual dividend is NT$1.85 per share, paid annual. The forward yield is 5.12% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
Genetics Generation Advancement Corp. (GGAC), headquartered in Taipei, Taiwan, specializes in providing advanced genetic testing and bioinformatics solutions. The company serves a diverse global clientele across Taiwan, Asia, Europe, and the Americas. GGAC offers a comprehensive array of genetic screenings tailored for various life stages and health needs. These include pre-conception, prenatal, and newborn testing, in addition to adult health management, cancer predisposition, and pharmacogenetic analyses. The company also collaborates with and provides services to institutional partners. Beyond its core genetic services, Genetics Generation Advancement Corp. extends its expertise to encompass life sciences, materials science, sophisticated laboratory informatics, enterprise quality management systems (EQMS), Manufacturing Execution Systems (MES), and efficient electronic data delivery solutions. Originally founded in 2008 as Genesis Genetics Asia Corp., the company officially rebranded and adopted its current name, Genetics Generation Advancement Corp., in February 2016.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$34.85-NT$1.95 (-5.3%)
Tien Liang BioTech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.7% below the high.
NT$16.90NT$0.00 (0.0%)
GenMont Biotech Incorporation’s quoted price sits in the lower half of its reported 52-week range, 14.43% below the high.
NT$90.50NT$0.00 (0.0%)
Acer Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.3% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$21.20+NT$0.20 (+0.95%)
Bioptik Technology Incorporation’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
NT$32.15+NT$0.45 (+1.42%)
Lagis Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.57% below the high.
NT$17.20+NT$0.05 (+0.29%)
Perfect Medical Industry Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.2% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
